Industry News


Bio-Rad Finalizes $70 Million AbD Serotec Acquisition

Norman Schwartz
  Norman    Schwartz

Bio-Rad Laboratories Inc, Hercules, Calif, has purchased AbD Serotec, UK, a division of MorphoSys AG, based in Germany, for approximately $70 million.

AbD Serotec is among the leading antibody manufacturers worldwide, offering more than 15,000 antibodies, kits, and accessories.

“With AbD Serotec’s comprehensive catalog of antibodies, we are able to offer our customers total assay solutions that can be validated on many of our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting,” says Norman Schwartz, president and CEO, Bio-Rad.

AbD Serotec has an ISO 9001- and ISO 13485-certified production facility in the UK, and other facilities in Germany and the United States.

[Source: Bio-Rad Laboratories]